Author Archives: Mark Ilhan
Join Oakwood Labs for a complimentary webinar on August 24th, 2021 at 11 a.m. EST. This webinar will discuss a corporate overview and Oakwood’s approach to development of extended-release and long-acting injectables.
Oakwood’s capabilities include the following:
- Pre-formulation development activities
- Feasibility studies
- Scale-up of formulation
- Manufacturing toxicology batches
- ICH compliant stability testing
- Clinical trial manufacturing (Phase I, II, III)
- Commercial aseptic GMP manufacturing
Reach Out to Oakwood Labs Today About Extended-Release Injectables
Contact us today to learn more about the extended-release solutions we can provide for your company. We look forward to hearing from you.
Since 1997, Oakwood Labs has remained a global industry leader in sustained release pharmaceutical development and technology, and our team is committed to offering contract development and manufacturing services to the pharmaceutical industry on a global scale. Continue reading to learn more about our sustained release technology and the many ways it is beneficial in pharmaceuticals.
Oakwood Labs is a leading company in the development and manufacture of sustained release pharmaceutical products, specifically microparticles for injection. We specialize in developing microparticle drug delivery formulations with in vivo release durations ranging from one week to one year. To learn more about our process for formulation, keep reading.
Oakwood Labs has been working as a contract development and manufacturing company, or CDMO, for over twenty years, and we have remained a leader in the pharmaceutical industry in this time.
With our microsphere-based drug delivery technology and our cGMP manufacturing facility, we are equipped to provide services from initial feasibility through commercial projection. Our technology allows for ease of scale-up throughout development without impacting finished product results. We can customize release durations from weeks up to one year.